- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07692321
Co-designing Enhanced Models of Care for First Nations Children at Risk for Childhood-onset Type 2 Diabetes
Co-designing Enhanced Models of Care for First Nations Children at Risk for Childhood-onset Type 2 Diabetes: The Next Generation Birth Cohort.
Studienübersicht
Status
Detaillierte Beschreibung
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Brandy A Wicklow, MD, MSc
- Telefonnummer: 204-787-1222
- E-Mail: bwicklow@hsc.mb.ca
Studieren Sie die Kontaktsicherung
- Name: Elizabeth AC Sellers, MD, MSc
- Telefonnummer: 204-787-3011
- E-Mail: esellers@hsc.mb.ca
Studienorte
-
-
Manitoba
-
Winnipeg, Manitoba, Kanada, R3E 3P4
- Children's Hospital Research Institute of Manitoba/University of Manitoba
-
Kontakt:
- Brandy A Wicklow, MD, MSc
- Telefonnummer: 204781222
- E-Mail: bwicklow@hsc.mb.ca
-
Kontakt:
- Research Coordinator
- Telefonnummer: 2042723064
- E-Mail: NextGenStudy@chrim.ca
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Kind
- Erwachsene
Akzeptiert gesunde Freiwillige
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria for the breastfeeding program:
- Pregnant women with type 2 diabetes or no diabetes.
- From self-identified Indigenous heritage (e.g., Cree, Oji-Cree, Métis, Anishinaabe, etc.) residing in the four Anisininew communities in the Island Lake region.
- Are delivering in Manitoba.
- Mother/Father and children must be biological family members.
Exclusion Criteria from the breastfeeding program:
- Parents or children with type 1 diabetes.
- Residing outside of Manitoba.
Inclusion criteria for the CGM pro
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
|---|---|
|
Co-develop and implement a community-based perinatal education and support program using navigators
The implementation of a community-based navigator to facilitate multiple points of pre and post-partum contact as well as individualized connection to preexisting and co-developed urban and northern pre- and post-natal supports, will increase rates of initiation and duration (≥6 month) of breastfeeding in the NextGen mothers from 58% to ≥75%.
|
Co-develop and implement a community-based perinatal education and support program using navigators to support breast feeding, maternal nutrition and activity, and early infancy/childhood nutrition and activity.
|
|
Extend the scope of the NextGen Cohort
Community based point of care HbA1c testing will improve access to annual screening for pre-diabetes and diabetes in the Next Gen Cohort.
CGM can detect early dysglycemia (below the threshold for the diagnosis of prediabetes) in young children at high risk for childhood-onset T2D.
In addition, we hypothesize that CGM use will be well tolerated and feasible in young children.
|
This will allow study participants to conduct earlier and more frequent screening for early dysglycemia, prediabetes and T2D.
We will investigate the use of continuous glucose monitoring (CGM) to detect early dysglycemia in the Next Gen cohort.
|
|
Co-develop and implement community led land-based programming for parent(s) and preschool children
Land-based community programming for caregivers and children aged 4-5 years is feasible and will encourage healthy nutrition choices and physical activity.
Ultimately, we hypothesize that this will improve the health and well-being of this high-risk population and improve cardiometabolic health.
|
Co-develop and implement community led land-based programming for parent(s) and preschool children aged 4-5 years to encourage traditional nutrition and activities to maintain wellness.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Proportion of mothers who initiate breastfeeding
Zeitfenster: 3 years
|
This will be for for both groups experiencing and not experiencing diabetes during the pregnancy, exclusivity of breastfeeding and breastfeeding continuation at 1, 3 and 6 months.
In addition, we will examine the growth trajectories of infants who are breastfed and compare them to infants who are not breastfed (from historical NextGen Cohort follow up and the current project).
|
3 years
|
|
Number of eligible children in the NextGen Cohort screened per community
Zeitfenster: 3 years
|
This is a feasibility pilot to determine if participants will be screened more frequently once there are point of care HbA1C machines in each community. Qualitative data on the feasibility and implementation of the screening program via interviews with the community health care workers and NextGen families to determine facilitators and barriers to screening in community and areas of improvement for the program. |
3 years
|
|
Percentage of sensor time with glucose > 7.8 mmol/L
Zeitfenster: 3 years
|
This is to determine the feasibility of using CGM with 6 and 7 year old children.
SD of sensor glucose levels (a summary measure of glycemic variability - amplitude, frequency and duration of fluctuation in glucose measurement) and 2. tolerability and feasibility of CGM use in this population.
|
3 years
|
|
Number of times the land-based wellness program ran
Zeitfenster: 3 years
|
Feasibility of establishing and implementing this program will be assessed by metrics including how often the program ran (bench marked against number of sessions planned), and number of children participating (benchmarked against number eligible).
|
3 years
|
|
Number of children who attend the land-based wellness programming
Zeitfenster: 3 years
|
3 years
|
|
|
Number of young adult leaders hired for the land-based wellness program
Zeitfenster: 3 years
|
We anticipate that another key outcome will be capacity building for young adult leaders who will work alongside Elders and develop skills in leadership, youth health and wellness, program evaluation, and land-based curriculum development
|
3 years
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Number of mothers who enroll and participate in the breastfeeding navigator-based program
Zeitfenster: 3 years
|
3 years
|
|
|
Number classes attended by mothers who participate in the breastfeeding navigator-based program
Zeitfenster: 3 years
|
3 years
|
|
|
Qualitative review of the land-based wellness program
Zeitfenster: 3 years
|
Barriers and facilitators of program success will be co-determined by Anisininew leaders through the evaluative process, and may include qualitative interviews with family participants and leaders and/or sharing circles lead by Elders and Knowledge keepers.
|
3 years
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Brandy A Wicklow, MD, MSc, University of Manitoba, Children's Hospital Research Institute of Manitoba
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Urogenitale Erkrankungen
- Erkrankungen des endokrinen Systems
- Weibliche Urogenitalerkrankungen und Schwangerschaftskomplikationen
- Stoffwechselerkrankungen
- Schwangerschaftskomplikationen
- Störungen des Glukosestoffwechsels
- Diabetes Mellitus
- Ernährungs- und Stoffwechselerkrankungen
- Schwangerschaftsdiabetes
- Diabetes mellitus, Typ 2
- Untersuchungstechniken
- Therapeutika
- Klinische Labortechniken
- Diagnosetechniken und Verfahren
- Diagnose
- Patientenversorgung
- Gesundheitsdienste
- Belegschaft und Dienstleistungen für Gesundheitseinrichtungen
- Fortpflanzung physiologische Phänomene
- Physiologische Fortpflanzungs- und Harnphänomene
- Blutchemische Analyse
- Klinische Chemie -Tests
- Diagnosetechniken, endokrin
- Überwachung, physiologisch
- Wochenbett
- Palliativpflege
- Kontinuierliche Glukoseüberwachung
- Laktation
Andere Studien-ID-Nummern
- 5308
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .